(Total Views: 738)
Posted On: 06/12/2020 1:41:08 PM
Post# of 154120
The study now allows the following pts as well:
" (2) Remdesivir, (3) convalescent plasma therapy ... and immunomodulatory treatments ... prior to study enrollment may be included and may continue to receive these agents as part of standard-of-care."
This should significantly help our enrollment eligibility. But might make the data analysis later on more difficult.
" (2) Remdesivir, (3) convalescent plasma therapy ... and immunomodulatory treatments ... prior to study enrollment may be included and may continue to receive these agents as part of standard-of-care."
This should significantly help our enrollment eligibility. But might make the data analysis later on more difficult.
(0)
(0)
